The bioequivalence (BE) test is a test in which the manufacturer compares the bioavailability of other same-component drugs, and if certain criteria are met, it is judged that “biologically equivalent” or “the drug effect is equal”. If a drug is biologically equivalent and therapeutic equivalent, it can be replaced by one another if the clinical usefulness and safety of these drugs are similar.

Based on this, BE studies are used to register and approve generic drugs.

This webinar explains how to perform BE analysis through the Phoenix IVIVC Toolkit with example data.

网络研讨会对谁最有帮助：

• Researchers studying generic drug and drug formulation
• Anyone interested in bioequivalence (BE)

主讲人：

KyeongSeok Hong
Manager of IT department, BITEK CHEMS